News | May 04, 2026
Lilly posts explosive Q1 2026 results
Lifts full-year outlook as obesity drug boom accelerates
Lifts full-year outlook as obesity drug boom accelerates
But acquisition charges drag earnings into loss
Market authorization for generic GLP-1 therapy strengthens company’s diabetes portfolio in Canada
Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
Approval for generic Semaglutide Injection strengthens CDMO partnership, enabling scalable supply from OneSource’s US FDA-approved Bengaluru facility
The company doses first patient in US study of Deraphan, as Dolby Ventures joins €53M Series B to support neuropsychiatric innovation
VESCOP, ENTOD Pharmaceuticals, and APTI-MSB host the event to bridge lab-to-clinic gap in eye care
The investigational therapy, MDX2003, is designed to go after cancer cells with a multi-pronged immune attack
Sanplatec is leading the industry in the field of containers and devices for cell culture and live transport
Stakeholders call for coordinated action on diagnostics, vaccines, and health system readiness as the monsoon season approaches
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
